$ABBV (+1,12 %)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway

$BMY (+0,75 %) Bristol-Myers Squibb seems to benefits from this +13%